Brain Cancer Clinical Trials in Houston

Showing 141-160 of 170 trials

A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma

NCT01547546

This open-label, multicenter, Phase I, dose-escalating study will evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy of GDC-0084 in patients with progressive or recurrent high-grade glioma. Stage 1 is the dose escalation part of the study. Stage 2, patients will receive GDC-0084 at a recommended dose for future studies.

Glioblastoma, Glioma

Genentech, Inc.29 participantsStarted Apr 2012

Los Angeles, California, United States • Boston, Massachusetts, United States • Boston, Massachusetts, United States +2 more locations

COMPLETEDPhase 1< 1 mile

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

NCT00326664

This phase I trial is studying the side effects and best dose of AZD2171 in treating young patients with recurrent, progressive, or refractory primary CNS tumors. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Childhood Atypical Teratoid/Rhabdoid TumorChildhood Central Nervous System Germ Cell TumorChildhood Cerebral Anaplastic Astrocytoma+18 more

National Cancer Institute (NCI)55 participantsStarted Mar 2006

San Francisco, California, United States • Washington D.C., District of Columbia, United States • Chicago, Illinois, United States +8 more locations

A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

Brain Cancer Trials in Other Cities

Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma

Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Brain Stem Glioma

Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme

Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors

Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors

Magnetic Resonance Temperature Imaging & Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors

Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA

Intraoperative Optical Imaging of Brain Function

Gene Testing to Help in the Diagnosis and Treatment of Childhood Brain Tumors

Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors

Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme

Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

AMG 595 First-in-Human in Recurrent Gliomas

Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse

Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme

Other Conditions in Houston